{"disease":{"id":"menopausal-vasomotor-symptoms","name":"menopausal vasomotor symptoms"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT00535288","title":"Dose-Finding Safety and Efficacy Trial of Org 50081 (Esmirtazapine) in the Treatment of Vasomotor Symptoms (177001/P06472/MK-8265-013)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":946,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT00184795","title":"Bleed Free Treatment of Menopausal Symptoms With New Ultra Low Dose Hormonal Combinations","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":576,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false},{"nct_id":"NCT02865538","title":"Evaluation of the Pharmacokinetics and Safety of BAY3427080 (NT-814) in Post-Menopausal Women With Vasomotor Symptoms","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":76,"lead_sponsor_name":"Bayer","has_results":true},{"nct_id":"NCT05325775","title":"Dose-ranging, PK, Safety, Efficacy Study of Osanetant in Patients With Moderate/Severe VMS Associated With Menopause","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":49,"lead_sponsor_name":"Acer Therapeutics Inc.","has_results":true}],"total":4},"guidelines":[],"source":"Drug Landscape verified database"}